DUBLIN–(BUSINESS WIRE)–The “Novel
Therapeutics for Duchenne Muscular Dystrophy” report has been
added to ResearchAndMarkets.com’s offering.
This Genetic Technology TOE depicts life sciences trends in therapeutics
for Duchenne’s muscular dystrophy. The topics covered range from gene
editing approaches to breakthrough muscle-on-a-chip innovations.
Clinical trial analysis of important investigational therapeutics for
Duchenne muscular dystrophy is also presented.
The complete gamut of genetic technology applications is covered
including the latest developments in omics technologies; genetic,
cellular, and alternative therapies; sequencing technologies; and
genetically altered animals and plants.
Key Topics Covered:
Recent Advances in Development of Novel Therapeutics for
Duchenne Muscular Dystrophy
- CRISPR-based Therapeutic in Development for Duchenne Muscular Dystrophy
- Multiple Treatment Development for Diverse DMD Population
- Solid Biosciences’ IGNITE DMD Clinical Trial to Resume
- Muscle-on-a-chip Platform for DMD Target Discovery
Clinical Trial Analysis and Key Contacts
Clinical Trial Analysis of Important Investigational Therapeutics for
Duchenne Muscular Dystophy
- Key Contacts
For more information about this report visit https://www.researchandmarkets.com/research/f5grgq/novel?w=4
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Nervous System Drugs , Musculoskeletal